Skip to main content

NW London CLRN Primary Care Meeting

One of the organisations I work with is the North-West London Comprehensive Local Research Network (CLRN). The North-West CLRN is one of 25 CLRNs across England which form part of the NIHR Comprehensive Clinical Research Network (CCRN). The CCRN provides support for clinical trials and other well designed studies in all areas of disease and clinical need. A key role for the CLRN is providing infrastructure support for studies on the NIHR Portfolio. Part of this infrastructure support is in primary care. On October 7th 2009, the CLRN held a meeting with some of the local GPs and other primary care staff who collaborate with the CLRN.

One of the key points arising from the meeting was the need to get more NIHR portfolio studies active in primary care in NW London. IT issues were also discussed, particularly the need for expertise to run queries on GP Electronic Patient Record Systems such as EMIS and Vision. The need to continue reimbursement of practice expenses and also to offer additional value to GPs through involvement in research design and planning, access to training etc was also discussed, as was the high administrative workload in processing invoices for service support costs from a large number of general practices. We also discussed the need to review current levels of Clinical Study Officer (CSO) provision and to increase this if warranted by a rising number of accruals. The need for high-level GP/academic input to overcome some of the blocks that can be present in primary care research by liaising with relevant senior staff in PCTs and practices was also raised.

We will take forward these points in future CLRN meetings and with the Primary Care Research Network for Greater London (PCRN-GL).

Comments

Popular posts from this blog

The Hidden Cost of Cheaper NHS Contracts: Losing Community Trust

NHS budgets are under considerable pressure. It is therefore unsurprising that many NHS Integrated Care Boards (ICBs) In England will aim to prioritise price in contract awards, But this approach is a significant threat to community-centred healthcare. While competitive tendering is a legally required, an excessive focus on costs in awarding NHS contracts risks overshadowing key factors such as established community trust, local expertise, and the long-term impact on continuity of care. This shift towards cheaper, often external, commercial providers threatens to cut the links between communities and their local health services. The argument that competitive tendering is solely about legal compliance, and not cost, is undermined by the very nature of such tendering, which by design encourages the lowest bid. This approach risks eroding the social fabric of local healthcare provision, where established relationships and understanding of specific community needs are essential. Establishe...

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...